The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Refixia.
Adults with haemophilia B who received a single dose Refixia (nonacog beta pegol; N9-GP) from Novo Nordisk, achieved greater total...
Novo Nordisk announced that the European Commission has granted marketing authorisation for Refixia for the treatment of adolescents and adults...
Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia B (congenital factor IX deficiency).